AMD Gene Therapy: One-Time Genetic Interventions for Retinal Preservation
Gene therapy for Age-Related Macular Degeneration (AMD) aims to provide a one-time treatment for a condition that traditionally requires frequent, invasive injections. By delivering specific genes directly to the retinal cells, this therapy turns the eye into a "bio-factory" that produces proteins to prevent the progression of vision loss.
For "wet" AMD, the goal is to introduce genes that produce anti-VEGF proteins, which stop the growth of abnormal, leaking blood vessels. For "dry" AMD (specifically geographic atrophy), researchers are targeting the complement system, delivering genes that regulate the overactive immune response responsible for the destruction of light-sensing cells in the macula.
The delivery mechanism typically involves an adeno-associated virus (AAV) vector, which is injected into the subretinal space. This vector acts as a vehicle, carrying the therapeutic DNA into the retinal cells without causing disease itself. Once the cells are "reprogrammed," they can continue to secrete the necessary proteins for years, significantly reducing the burden on the patient and the healthcare system.
Clinical trials in 2026 are showing promising results in stabilizing vision and preserving retinal architecture. While the procedure requires specialized surgical expertise, the prospect of a long-lasting solution for a leading cause of blindness is a major milestone in ophthalmology. It represents the transition from managing symptoms to fundamentally altering the genetic environment of the diseased eye.